Literature DB >> 35092501

The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma.

Jianpeng Li1,2,3, Jinlong Cao1,2,3, Cheng Liang1,2,3, Ran Deng1,2,3, Pan Li1,2,3, Junqiang Tian4,5,6.   

Abstract

The tumor immune microenvironment (TIME) and N6-methyladenosine (m6A) are related to the progression of several types of cancer. Nevertheless, the impact of m6A on the TIME of clear cell renal cell carcinoma (ccRCC) remains unclear. This study used an unsupervised clustering algorithm to divide the samples into distinct subgroups. The single sample gene set enrichment analysis (ssGSEA) algorithm to estimate the TIME. The correlation between m6A regulators and immune cells in different subgroups was calculated using Spearman analysis. At last, the relationship between IGF2BP2 and HMGA2 was validated in several datasets, including TCGA-KIRC, GEO, and HPA datasets. We found that m6A regulators were differently expressed in several clinical groups. Based on the expression of m6A regulators, we divided the samples into three subgroups. Then, the survival analysis for these three subgroups showed that the cluster 2 subgroup had poor overall survival (OS). Further, we found that IGF2BP2 and IGF2BP3 were essential components in the cluster 2 subgroup using the principal component analysis (PCA) algorithm. In addition, the expression of these two genes was significantly correlated with survival time. At last, we found that HMGA2 was significantly correlated with IGF2BP2 in several datasets, which indicated that HMGA2 is an essential role in affecting IGF2BP2 regulating the TIME. There is a close correlation between m6A regulators and TIME. Moreover, IGF2BP2 is related to the progression of ccRCC and plays an essential role in affecting the TIME.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  HMGA2; IGF2BPs; Tumor immune microenvironment; ccRCC; m6A

Mesh:

Substances:

Year:  2022        PMID: 35092501     DOI: 10.1007/s12032-021-01645-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  37 in total

Review 1.  The immune microenvironment: a major player in human cancers.

Authors:  W H Fridman; R Remark; J Goc; N A Giraldo; E Becht; Scott A Hammond; D Damotte; M-C Dieu-Nosjean; Catherine Sautès-Fridman
Journal:  Int Arch Allergy Immunol       Date:  2014-05-13       Impact factor: 2.749

2.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

3.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Authors:  Brian I Rini; Thomas Powles; Michael B Atkins; Bernard Escudier; David F McDermott; Cristina Suarez; Sergio Bracarda; Walter M Stadler; Frede Donskov; Jae Lyun Lee; Robert Hawkins; Alain Ravaud; Boris Alekseev; Michael Staehler; Motohide Uemura; Ugo De Giorgi; Begoña Mellado; Camillo Porta; Bohuslav Melichar; Howard Gurney; Jens Bedke; Toni K Choueiri; Francis Parnis; Tarik Khaznadar; Alpa Thobhani; Shi Li; Elisabeth Piault-Louis; Gretchen Frantz; Mahrukh Huseni; Christina Schiff; Marjorie C Green; Robert J Motzer
Journal:  Lancet       Date:  2019-05-09       Impact factor: 79.321

4.  Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.

Authors:  Xu Lei; Yu Lei; Jin-Ke Li; Wei-Xing Du; Ru-Gui Li; Jing Yang; Jian Li; Fang Li; Hua-Bing Tan
Journal:  Cancer Lett       Date:  2019-11-12       Impact factor: 8.679

5.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?

Authors:  Giandomenico Roviello; Silvia Paola Corona; Gabriella Nesi; Enrico Mini
Journal:  Ther Adv Med Oncol       Date:  2019-08-05       Impact factor: 8.168

8.  Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma.

Authors:  Zedan Zhang; Enyu Lin; Hongkai Zhuang; Lu Xie; Xiaoqiang Feng; Jiumin Liu; Yuming Yu
Journal:  Cancer Cell Int       Date:  2020-01-28       Impact factor: 5.722

9.  m6A modification patterns and tumor immune landscape in clear cell renal carcinoma.

Authors:  Jiehui Zhong; Zezhen Liu; Chao Cai; Xiaolu Duan; Tuo Deng; Guohua Zeng
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.